Health Canada Approves Libtayo for High-Risk Cutaneous Squamous Cell Carcinoma
Health Canada has issued a Notice of Compliance for Regeneron’s immunotherapy Libtayo as an adjuvant treatment for adults with high-risk cutaneous squamous cell carcinoma…